-
公开(公告)号:US07745157B2
公开(公告)日:2010-06-29
申请号:US10783259
申请日:2004-02-20
CPC分类号: A61K39/39 , A61K2039/55588
摘要: The present invention relates to an adjuvant derived from human lymphocytes. The adjuvant can be used in combination with traditional vaccines or cancer immunotherapy, to enhance the response of the patient's immune system to the vaccine or other immunotherapeutic agent. The adjuvant is derived from the supernatant collected from cultured activated lymphocytes.
摘要翻译: 本发明涉及来自人淋巴细胞的佐剂。 佐剂可以与传统疫苗或癌症免疫治疗组合使用,以增强患者免疫系统对疫苗或其他免疫治疗剂的反应。 佐剂来自培养的活化淋巴细胞收集的上清液。
-
公开(公告)号:US08088397B2
公开(公告)日:2012-01-03
申请号:US12824577
申请日:2010-06-28
CPC分类号: A61K39/39 , A61K2039/55588
摘要: The present invention relates to an adjuvant derived from human lymphocytes. The adjuvant can be used in combination with traditional vaccines or cancer immunotherapy, to enhance the response of the patient's immune system to the vaccine or other immunotherapeutic agent. The adjuvant is derived from the supernatant collected from cultured activated lymphocytes.
摘要翻译: 本发明涉及来自人淋巴细胞的佐剂。 佐剂可以与传统疫苗或癌症免疫治疗组合使用,以增强患者免疫系统对疫苗或其他免疫治疗剂的反应。 佐剂来自培养的活化淋巴细胞收集的上清液。
-
公开(公告)号:US20100266534A1
公开(公告)日:2010-10-21
申请号:US12824577
申请日:2010-06-28
IPC分类号: A61K38/19 , A61K38/20 , A61K38/21 , A61K39/00 , A61K39/21 , A61K39/29 , A61K39/08 , A61K39/05 , A61P31/04 , A61P31/18 , A61P31/14 , A61P31/20
CPC分类号: A61K39/39 , A61K2039/55588
摘要: The present invention relates to an adjuvant derived from human lymphocytes. The adjuvant can be used in combination with traditional vaccines or cancer immunotherapy, to enhance the response of the patient's immune system to the vaccine or other immunotherapeutic agent. The adjuvant is derived from the supernatant collected from cultured activated lymphocytes.
摘要翻译: 本发明涉及来自人淋巴细胞的佐剂。 佐剂可以与传统疫苗或癌症免疫治疗组合使用,以增强患者免疫系统对疫苗或其他免疫治疗剂的反应。 佐剂来自培养的活化淋巴细胞收集的上清液。
-
-